I’m Professor Varun Chaudhary from McMaster University. In this video, we’ll focus on key insights from the pivotal trials for EYLEA 8 mg, specifically looking at the PULSAR and PHOTON studies. Before ...

Gore recently launched its silicone-free GORE IMPROJECT Plunger for 0.5-mL pre-filled syringes for the delivery of ophthalmic drugs. W. L. Gore and associates (Gore) announced the launch of its ...

Now may be a good time to initiate a small position on the dip. Regeneron is facing biosimilar competition for Eylea, one of its biggest growth drivers. In the first quarter, the company's revenue ...

The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL ...

Launched in 2022, the drug has robbed Eylea of its dominance of the market—especially in the U.S. Regeneron also said sales were affected in the period by an 11% sequential decrease in ...

Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label extension for Eylea 8 mg ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leading biopharmaceutical company with a market capitalization of $62.17 billion, finds itself at a critical juncture as it navigates challenges to its ...